HCW Biologics' HCW11-018b shows novel cis-binding, shrinks tumors; IND due H1 2027
HCW Biologics’ lead tetra-valent T-cell engager HCW11-018b demonstrated potent antigen-specific anti-pancreatic cancer activity by significantly shrinking tumors and preventing metastasis in xenograft models through a novel cis-binding mechanism activating only in the tumor microenvironment. The company plans to file an IND for HCW11-018b in the first half of 2027.
1. Preclinical Efficacy of HCW11-018b
HCW11-018b, a tetra-valent T-cell engager built on the TRBC platform, achieved significant tumor shrinkage and prevented metastasis in pancreatic cancer xenograft models. Its antigen-specific action and high tolerability profile derive from targeted activation within the tumor microenvironment.
2. Novel Cis-Binding Mechanism
The engager employs a cis-binding approach that masks certain receptors to inhibit trans-binding and regulate immune cell reactivity. Activation occurs exclusively in the tumor microenvironment, enhancing therapeutic index and minimizing off-tumor effects.
3. IND Application Timeline
HCW Biologics projects submission of an Investigational New Drug application in the first half of 2027 to initiate clinical trials in pancreatic cancer patients. This timeline leverages established GMP manufacturing processes to support rapid transition to human studies.